Back
Press release

flowerhaus

  • flowerhaus
  • Posted by flowerhaus
25/11/2019
5 min read

Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

Lorem ipsum dolor sit amet, consectetur adipiscing elit....

Read More
  • flowerhaus
  • Posted by flowerhaus
11/11/2019
5 min read

Inceptua appoints new CEO

Lorem ipsum dolor sit amet, consectetur adipiscing elit....

Read More
  • flowerhaus
  • Posted by flowerhaus
29/10/2019
4 min read

The 21st Century Cures Act: Turn your obligations into an advantage

The 21st Century Cures Act and Expanded Access...

Read More
  • flowerhaus
  • Posted by flowerhaus
17/08/2019
3 min read

Pre-Approval Access Policy

Policies on pre-approval access (‘early access’, ‘expanded access’...

Read More
  • flowerhaus
  • Posted by flowerhaus
03/07/2019
1 min read

Navigating the Clinical Trial Supply Route in China

Assuring Integrity from Start to Finish Inceptua has...

Read More
  • flowerhaus
  • Posted by flowerhaus
28/06/2019
3 min read

Small Data for a Big Benefit

Lorem ipsum dolor sit amet, consectetur adipiscing elit....

Read More
  • flowerhaus
  • Posted by flowerhaus
27/06/2019
5 min read

Inceptua Q&A: Comparator Sourcing for Clinical Trials

Lorem ipsum dolor sit amet, consectetur adipiscing elit....

Read More
  • flowerhaus
  • Posted by flowerhaus
16/05/2019
4 min read

HAEi Global Access Program Provides Life-saving Medication

Lorem ipsum dolor sit amet, consectetur adipiscing elit....

Read More
  • flowerhaus
  • Posted by flowerhaus
09/04/2019
1 min read

Expediting Access to Rare Disease Therapies in Europe

Exploring Multi-Stakeholder Approaches Globally there are approximately 7,000...

Read More
  • flowerhaus
  • Posted by flowerhaus
20/03/2019
3 min read

Considering an access program for your asset?

Ask Inceptua Are you in the early stages...

Read More
BIO

CEO and Board Member

Stefan Fraenkel

Stefan Fraenkel is the CEO of the Inceptua Group and is also on the Inceptua Board. He has extensive experience in the pharmaceutical industry. Before joining Inceptua, he held senior management positions at Sobi (Swedish Orphan Biovitrum), Sweden’s largest publicly listed specialty pharmaceutical company, leading Marketing & Sales and serving as Head of Corporate Development and Strategy.

Previously, Stefan worked at Pfizer and Wyeth in international commercial leadership roles across Europe and the USA, gaining deep insights into global pharmaceutical markets and strategies. Stefan has also spent part of his career in management consulting. Stefan holds a PhD in International Economics, an MBA, and a BSc in Engineering.

BIO

Member of the Board

Chris Hasslinger

Chris Hasslinger is a Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2023 and is responsible for sourcing and evaluating new investment opportunities and general portfolio company management. Mr. Hasslinger has nearly three decades of experience in healthcare and technology strategy and deal-making within the industry as well as in investment banking and private equity. He has extensive M&A experience, having closed over $20 billion in transaction value, and has established and structured a number of large commercial partnerships.

BIO

Executive Vice Chairman

Alan Raffensperger

Alan Raffensperger has a robust leadership background in the pharmaceutical industry, having served as CEO of Inceptua and COO of Sobi (Swedish Orphan Biovitrum), along with significant international executive roles at Amgen, Roche, and Pharmacia.

He has also been CEO for venture capital-owned medical device companies, showcasing his versatility in healthcare leadership. Alan’s early career as an advanced life support paramedic provided a strong foundation in emergency healthcare.

He holds an MBA and a BA in Emergency Health Care Management.

BIO

Member of the Board

Blake Goodner

Blake Goodner is a founder member of the investment firm Bridger Capital. He previously worked as a healthcare analyst at Tiger Management and a healthcare investment banker at Morgan Stanley. He currently serves as an advisor and board member for a range of healthcare companies. Mr. Goodner has been a member of the Trinity College Board of Visitors and the Duke Annual Fund Executive Committee. He is a current advisory board member with The Duke Margolis-Center for Health Policy.

BIO

Member of the Board

Adam Feinstein

Adam Feinstein is the Managing Partner of Vesey Street Capital Partners. Mr. Feinstein has 30 years of investment experience exclusively in the healthcare services sector. Prior to founding Vesey Street Capital Partners in 2014, he was a Managing Director on Wall Street and a healthcare industry executive. He held the position of Senior Vice President of Corporate Development, Strategic Investments, and Office of the Chief Executive Officer at LabCorp. Before his tenure at LabCorp, he spent 14 years as the Managing Director in Equity Research at Lehman Brothers/Barclays Capital. Mr. Feinstein is the Chairman of VSCP’s investment committee. He is also actively involved in working with portfolio company executives and sourcing new investment opportunities. At the same time, he oversees all of the firm’s investment activities and employees.

BIO

Member of the Board

Larry Marsh

Larry is a General Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2016, and currently sits on the Board of QualityMetric, Safecor Health, and HRGi. He is responsible for portfolio company management and for evaluating new investment opportunities. Prior to VSCP, Larry was EVP, New Market Development & Chief Strategy Officer at Fortune 10 AmerisourceBergen. Prior to that, Larry was the #1 ranked Healthcare Technology & Distribution analyst on Wall Street for over a decade, at Barclays, Lehman Brothers, Salomon Smith Barney, and Wheat First Butcher & Singer. Larry worked with Adam, Bryan, Dan, and Joe at Barclays and Lehman. Larry received a B.S. in Economics & Management as well as an M.B.A. from the University of Richmond, and an M.P.H. from Columbia University.

BIO

Member of the Board

Heyward Donigan

Heyward Donigan is a seasoned healthcare CEO, Board Member, and Private Equity Advisor with broad industry experience and a track record of profitable growth. From 2019 to 2023, Ms. Donigan served as Rite Aid’s president and chief executive officer, making her one of the few women CEOs of a Fortune 500 company. While at Rite Aid, Ms. Donigan led the company to through a major brand, merchandise and technology transformation, debt reduction/refinancing, while also leading the company through a pandemic. Ms.Donigan is currently a strategic advisor to Vesey Street Capital Partners, Arima Health, and a board member of OnMed.

BIO

Executive Chairman

Doug Cook

Doug Cook is the Executive Chairman at Inceptua. Mr. Cook began his career driving the early success of Livingston Healthcare, leading to the purchase by UPS to become what is today UPS’s Global Healthcare business. After Livingston Healthcare, Mr. Cook moved to AmerisourceBergen (now called Cencora/COR) in 1998 and had an impressive career overseeing most of Cencora’s high growth, manufacturer-facing business. Mr. Cook ultimately served as the Executive Vice President, President Commercialization and Animal Health for COR.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

CONTINUE
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE